L Aarons(1) , LP Balant(2) , F Mentre(3) , PL Morselli(4) , M Rowland(1) , J-L Steimer(5) , S Vozeh(6)
Practical Experience and Issues in Designing and Performing Population Pharmacokinetic/Pharmacodynamic Studies
|
J. Bennet(1) , LF.Lacey(2) , K. Koch(3) , A. Bye(2)
Determination of the Population Pharmacokinetics of Bismuth from GR122311X in Healthy Volunteers using the Gibbs Sampler Bayesian Method.
|
D. Breilh, C. Pobel, M.C. Saux
Non Linear Pharmacokinetics of Ethanol. Analysis of Patients with NONMEM. Study I
|
D. Breilh, C. Pobel, MC. Saux
Non Linear Pharmacokinetics of Ethanol. Population Model with NONMEM After an Optimal Sampling Duration. Study II
|
D. Breilh, C. Pobel, P. Rispal, MC. Saux
Population of Vancomycine with Continuous Infusion Administered in Neutropenic Patients Modeling on NPEM2-NONMEM-P-PHARM
|
D. Breilh(1) , C. Pobel(1) , C. Roth(2) , M.C. Saux(1) , G.Janvier(2)
Sufentanyl Pharmacokinetic-Pharmacodynamic Modelling (PK/PD) on NONMEM in 10 Patients with Coronary Surgery
|
J. Bres, D. Cupissol, J. Nouguier-Soule, Ch. Gestin-Boyer, Ü. Büttner, B. Palomba
Population Distribution of Platinum Pharmacokinetic Parameters for Dosage Recommendations of CDDP and Adaptive Control during the Course of Therapy, using different Softwares.
|
N.J. Bruce, A.H. Thomson, H.L. Elliott
Population Pharmacokinetics of Tacrolimus in Liver Transplant Patients
|
P.Burtin, J. vanBree, F. Mentre, S. Hensel, J.L. Steimer
A Prospective Evaluation of Sparse Sampling for Toxicokinetics in the Course of Drug Development.
|
B Charpiat(1) , V Breant(1) , G Tissier(1) , J M.Sab(1) , P Maire(2) , RW Jelliffe(3)
How Many Patients and Blood Levels for Population Pharmacokinetic Analysis? a Study with a One Compartment Model.
|
Valirie Cosson, Eliane Fuseau, Ph D, Constantin Efthymiopoulos, Alan Bye, Ph D
From Animal to Man
|
MJ du Preez(1) , JH Botha(1) , ML McFadyen(2) and M. Adhikari(3)
Effect Concentration Relationships of Theophylline in Apnoea of Prematurity
|
A.C. Falcao(1,2) , M.M. Fernandez de Gatta, A. Dominguez-Gil, J.M. Lanao
Sampling Strategies for Population Analysis: a Theoretical Study to Support Practical Results Obtained with Caffeine in Premature Neonates
|
Karin E. Fattinger, Davide Verotta, Herve C. Porchet, Alain Munafo, Jean-Yves le Cotonnec and Lewis B. Sheiner
Pharmacokinetic/-Dynamic Modeling of a Bivariate Control System: Luteinizing Hormone and Testosterone Response to GnRH Antagonist Antide
|
L. Harnisch(1) , W. Weber(1) , E. Sultan(2)
Population Approach to Nonlinear Pharmacokinetics of a New Drug under Development
|
D. Hille(1) , R. Bruno(2) , S. Durrleman1, L. Sheiner(3) ,
Relationship Between the Pharmacokinetics and the Pharmacodynamics of Taxotere (RP56976, DOCETAXEL) in Cancer Patients
|
N.S. Houwing, F. Rombout
Population Pharmacokinetics: Effect of Sampling Scheme on Parameter Estimation.
|
Niclas Jonsson(1) , Janet R Wade(1) , Gun Almqvist(2) and Mats O Karlsson(1)
Discrimination between Rival Dosing Histories
|
Karlsson M.(1) , Milligan P.(2) , Nichols D.(2)
Determination of Relative Potency for Drug and Metabolite in Vivo
|
F. Keller(1) , D. Zellner(1) , T. Frankewitsch(1) , M.Giehl(2)
Population Kinetics and Individual Drug Dosage Adjustment
|
C. Laveille, N. Frey, G. Lerebours, G. Resplandy, Jochemsen, R.
Population Pharmacokinetic-Pharmacodynamic of a New Specific Bradycardic Agent: S-16257
|
Graham Lockwood, Gary Maier
The use of Population Pharmacokinetic Approaches to Aid in the Assessment of Bioequivalence for a Highly Variable Drug
|
M. Looby, U. Wünscher, M. Weiss
NONMEM in Destructive Sampling Experiments; Experiences with the Toxicokinetics of Dibromchloromethane
|
SF Marshall, HL Elliott, and PA Meredith
Prediction of Simvastatin Pharmacological Response: A Population Analysis
|
M.T. Mateu-Garcia, J.J. Perez-Ruixo, V.G. Casabo-Alos, N.V. Jimenez-Torres
Apache II as Predictor of Gentamicin Pharmacokinetic Parameters in Critical Ill Patients
|
F. Mesnil(1) , F. Mentre(1) , C. Dubrue(2) , A. Mallet(1)
Population Pharmacokinetics Analysis of Mizolastine: Estimation with NPML and Validation
|
P. Milligan(1) , M. Karlsson(2) , D. Nichols(1)
High Variability Compounds - High Risk for Developers?
|
JPR Monteleone and NHG Holford
Modeling Interoccasion Variability in Toxicokinetics and Toxicodynamics
|
L.S. Murray(1) , D.I. Jodrell(2) . J.G. Morrison(2) , A.W. Kelman(1) , D.J. Kerr(2) , B.Whiting(1) & S.B. Kaye(2)
A Population Approach to Predicting Post-Treatment Levels of Epirubicin in Patients with Advanced Breast Cancer
|
Helene Peyriere(1) , Janine Bres(1) , Dominique Hillaire-Buys(2)
Performance Evaluation of Three Softwares for Bayesian Predictions of Teicoplanin Pharmacokinetic Parameters: APIS MICROPHARM, PKS Abbott
|
S. Rietbrock, S. Harder, H. Baas
Influence of Apomorphine on the PK/PD-Relationship of Levodopa: Two-Step versus NONMEM Analysis
|
Ferdie Rombout
An Industrial Perspective: Practical Stages in Model Development
|
M. Sandström(1) , A. Freijs(1) , R. Larsson(2) , P. Nygren(3) , J. Bergh(3) , M-L. Fjällskog(3) , M.O. Karlsson(1) ,
Lack of Relationship between Systemic Exposure for the Component Drugs of the FEC Regimen in Breast Cancer Patients
|
D. Santos Buelga, M.F. Delgado Iribarnegaray, M.J. Garca, M.J. Otero, A. Falcao, A. Dominguez-Gil
Carbamazepine Population Pharmacokinetics in Children
|
Rik Schoemaker and Adam Cohen
Estimation of Kinetic/Dynamic Curves With Insufficient Information for Each Individual Using Non-Linear Mixed Effect Modelling
|
M. Tod(1) and Jean-Marie Rocchisani(2)
An Algorithm for the Estimation of Optimal Sampling Times in Pharmacokinetics by the ED, EID and API Criteria
|
M. Tod*(1) , C. Padoin(1) , C. Minozzi(2) , J. Cougnard(2) , O. Petitjean(1)
A Population Pharmacokinetic Study of Isepamicin in ICU Patients
|
B. Tranchand, S. Urien, C. J. Ardiet
Population Pharmacokinetics of Intravenous Melphalan: NONMEM and MP2 Analysis
|
Saik Urien (I.N.S.E.R.M.)
MP2 (MicroPharm Population): A Windows Application for Population Pharmacokinetics
|
Janet R Wade(1) , Britt-Marie Emanuelsson(2) , Lars L Gustafsson(3) ,
A Population Approach Enables the Characterisation of Saturable Protein Binding for Ropivacaine
|
Jon Wakefield
42 Bayesian Individualization via Sampling-Based Methods.
|
J Wakefield, G Strehlau
Software product POPKAN; Population pharmacokinetic modelling and analysis
|
W. Weber(1) , L. Harnisch(1) , M. Zimmer(1) , P. Crause(2) , B. Katgely(1)
Optimization of a ''First Dose in Man'' Study using a NONMEM Model for Mammals
|
W. Weber*, L. Harnisch, M. Zimmer, C. Rokitta, P. Mendes
New Evidence for a Triexponential Disposition of Cefotaxime
|
